-+ 0.00%
-+ 0.00%
-+ 0.00%

Oncolytics Biotech Announces Its Data From REO 022 Trial In Metastatic Colorectal Cancer Shows 19.5-Month Median Duration Of Response In Second-Line KRAS-Mutant MSS mCRC Participants

Benzinga·05/04/2026 13:02:47
Listen to the news

Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, an investigational, systemically delivered immunotherapy that has been shown to activate innate immune-sensing pathways, today announced new durability data in metastatic colorectal cancer ("mCRC"), demonstrating meaningful and sustained clinical benefit in patients with RAS-mutant, microsatellite-stable ("MSS") disease.

Pelareorep-based combination therapy demonstrated a 19.5-month median duration of response in second-line ("2L") KRAS-mutant MSS mCRC patients in the REO 022 study, compared to historical benchmarks of approximately 4–6 months in this setting.1 Additional data from this study include an objective response rate of 33% for patients receiving pelareorep, bevacizumab, and FOLFIRI, tripling the 6-11% for the standard of care.